Benefits of Applying Nanotechnologies to Hydrogels in Efficacy Tests in Osteoarthritis Models-A Systematic Review of Preclinical Studies.
Chiara DelbaldoMatilde TschonLucia MartiniMilena FiniGiorgia CodispotiPublished in: International journal of molecular sciences (2022)
Osteoarthritis (OA) is a severe musculoskeletal disease with an increasing incidence in the worldwide population. Recent research has focused on the development of innovative strategies to prevent articular cartilage damage and slow down OA progression, and nanotechnologies applied to hydrogels have gained particular interest. The aim of this systematic review is to investigate the state of the art on preclinical in vitro and in vivo efficacy studies applying nanotechnologies to hydrogels in OA models to elucidate the benefits of their applications. Three databases were consulted for eligible papers. The inclusion criteria were in vitro and in vivo preclinical studies, using OA cells or OA animal models, and testing hydrogels and nanoparticles (NPs) over the last ten years. Data extraction and quality assessment were performed. Eleven papers were included. In vitro studies evidenced that NP-gels do not impact on cell viability and do not cause inflammation in OA cell phenotypes. In vivo research on rodents showed that these treatments could increase drug retention in joints, reducing inflammation and preventing articular cartilage damage. Nanotechnologies in preclinical efficacy tests are still new and require extensive studies and technical hits to determine the efficacy, safety, fate, and localization of NPs for translation into an effective therapy for OA patients.
Keyphrases
- knee osteoarthritis
- systematic review
- oxidative stress
- case control
- drug delivery
- cell therapy
- drug release
- hyaluronic acid
- induced apoptosis
- extracellular matrix
- end stage renal disease
- rheumatoid arthritis
- tissue engineering
- newly diagnosed
- wound healing
- chronic kidney disease
- randomized controlled trial
- emergency department
- risk factors
- electronic health record
- single cell
- endoplasmic reticulum stress
- adverse drug
- patient reported outcomes
- cell cycle arrest